Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer

NCT00243854 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Tarceva

Sponsor

Indiana University

Collaborators

[object Object]